Eph receptor B2 (EPHB2) Human shRNA Plasmid Kit (Locus ID 2048)

Specifications

Product Data
Product Name	Eph receptor B2 (EPHB2) Human shRNA Plasmid Kit (Locus ID 2048)
Locus ID	2048
UniProt ID	P29323
Synonyms	BDPLT22; CAPB; DRT; EK5; EPHT3; ERK; Hek5; PCBC; Tyro5
Vector	pGFP-C-shLenti
Format	Lentiviral plasmids
Kit Components	EPHB2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 2048). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
RefSeq	NM_001309192, NM_001309193, NM_004442, NM_017449, NM_017449.1, NM_017449.2, NM_017449.3, NM_017449.4, NM_004442.2, NM_004442.3, NM_004442.4, NM_004442.5, NM_004442.6, NM_004442.7, BC007903, BC018763, BC041017, BC067861, BC146296
Summary	This gene encodes a member of the Eph receptor family of receptor tyrosine kinase transmembrane glycoproteins. These receptors are composed of an N-terminal glycosylated ligand-binding domain, a transmembrane region and an intracellular kinase domain. They bind ligands called ephrins and are involved in diverse cellular processes including motility, division, and differentiation. A distinguishing characteristic of Eph-ephrin signaling is that both receptors and ligands are competent to transduce a signaling cascade, resulting in bidirectional signaling. This protein belongs to a subgroup of the Eph receptors called EphB. Proteins of this subgroup are distinguished from other members of the family by sequence homology and preferential binding affinity for membrane-bound ephrin-B ligands. Allelic variants are associated with prostate and brain cancer susceptibility. Alternative splicing results in multiple transcript variants. [provided by RefSeq, May 2015]
shRNA Design	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
Performance Guaranteed	OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.